Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Frustrating how thin this was earlier today. I guess not many knew about this. I would have held on if it wouldn't have behaved like crap.
Well Jesus Christ. Glad I didn't buy at 8 cents looking for a bounce! So much for solar shingles Tesla competitor.
Nice day. I knew all it needed was some volume. I took most of my bags at ~$4.05. I plan to be back in in high 2s. And leave my phone not on silent so i get price trigger alerts earlier next time!
Well, that sucks! RIP Pernix. Website now reroutes to curraxpharma.com
Merger is APPROVED at the special meeting today.
NCC-1701-F? What will the designation of the new Enterprise be?
This has 32,000 in premarket volume. But it is a pink sheet ticker still. How can it have premarket volume?
I don't suppose this will be a sympathy to solo & fuv...
AIPT receives $1,370,000 Investment from CEO and Director, Carl Schwartz
Some more actual insider buying, cool. and 6 units sold to Yale University.
What is the CC phone # to ask a question? I know the audio is online http://ir.tesla.com/events-and-presentations
2+ within a few months IMO
Email from Bob Myers on why the delay; "there are no difficulties other than trying to complete a massive S-4/combined proxy for an annual meeting."
https://stocktwits.com/danwat1234/message/138889978
Interesting how NO OTC MJ stocks are moving despite TLRY, NBEV, IGC have gone crazy.
Another strong day, it could form an ascending triangle with new highs. Got to finalize that merger
Zero volume today??
CC audio;
So, people that held when the symbol became deleted, lost it all correct?
Bullish
I have high hopes for SKLN as well. I see a big move eventually. In the meantime, stay even by selling the news (near the top hopefully). News tends to happen rather frequently, hopefully even more when Helomics and CytoBioscience JV with SKLN, giving news to SKLN to give a reason for Algos to buy.
WRONG! I sold at 1.31 Premarket! <-- "Their co-criminals shorted from $1.30 today "
I sold about 20K shares, ate up that 25K bid at 1.31 in premarket this morning. That was me. Then it just shriveled up into open and from there was crappy.
I sell the news, that is the play for the stock right now.
News came! With multiple Form 4 right to Buy at $1.01 today, and a sales update; 6 Streamway units sold this month alone, versus only 10 sold in all of 2017! Making progress!
Helomics involves cancer/tumor research and AI. Good news catalyst possibilities down the road after JV completes. Mgmt is 'excited'.. though bagholders are not happy. Have a stressful, horrible weekend everyone!
Trade at 0.0000 just went through.. 270,000 shares at 15:30:52 ET.
Bottom line, dead company. Dead stock at least. Ignore unless big price action.
Any day down merger should go thru and we go boom big time! Patience pays
To the Moon! LEDs has run up to 2.9 once and then 2.5 or so recently. Might finally be waking up.
Bullish! Obvious buy because when the merger comes thru, it ought to bounce to above $2 easily. Patience pays! But others won't climb in until the news hits, because impatient.
..Tangiers? The reason was form 4 selling but we haven't seen any such form for weeks. Possibly straight dilution now?
The bid/ask spread is easily about 50% either way... perhaps the stock will rage at some point but don't count on it
I want to hit my head on the wall as well! I had 25K grand at 0.75 but sold near the same price before it dipped down to ~0.47 because I thought dilution may of been happening. But then it soon jumped just above $1.00 and I didn't buy back in for some reason. (EDIT: because I thought SKLN would jump big time upon CE mark and then got burned during the CC call...)
It is interesting that there was no buying pressure for this stock for a long time, like people didn't know bitcoin was going to increase in price, that things were in MGT's pipeline.. and then all of a sudden it was followed by bitcoin investors to keep it above $1 and then of course ballooned with the bitcoin rally.
People didn't know that MGT existed in the 0.7 range until some time?
Good ER and CC, just a matter of time before a pop at least (rinse & repeat) or moon (rejoice).
They sure cut the CC short!
Skyline Medical signs merger agreement with Cytobioscience!! ER on August 14th (or premarket of 15th) with CC on the 15th!
Aug 9 (Reuters) - Skyline Medical Inc(SKLN):
* Skyline Medical(SKLN) signs definitive merger agreement with Cytobioscience
* Skyline Medical(SKLN) - upon closing of acquisition, Garvin will be named president of Skyline Medical(SKLN) and will be appointed to Skyline Medical(SKLN) board
* Says acquisition has been approved by boards of directors of both companies
* Skyline Medical Inc(SKLN) - ?under terms of agreement, Skyline will pay owners of Cytobioscience at closing 19.8% of outstanding common shares?
* Skyline Medical Inc(SKLN) says upon closing of acquisition Schwartz will remain chief executive officer and a director of Skyline Source text for Eikon: Further company coverage:
--------------------
Definitive Merger Agreement signed, calling for issuance of Skyline common and preferred stock
Skyline Medical (SKLN) expands revenue stream into growth markets with CytoBioscience for their ion channel screening and protein solubility analytics, in vitro contract research services and support products; gains new opportunities for STREAMWAY® System sales
CytoBioscience has an order backlog of $6 million
CytoBioscience CEO Dr. James Garvin to become president of Skyline Medical(SKLN); Dr. Garvin and one other CytoBioscience designee to be named Skyline Medical(SKLN) directors
Transaction expected to close by September 30, 2017
MINNEAPOLIS, Aug. 09, 2017 (GLOBE NEWSWIRE) -- Skyline Medical Inc.(SKLN) (“Skyline” or “the Company”), producer of the FDA-approved STREAMWAY® System for automated, direct-to-drain medical fluid disposal, announces the signing of a definitive agreement to merge with CytoBioscience, a privately held biomedical company. Under the terms of the agreement, Skyline will pay the owners of CytoBioscience at closing 19.8% of the outstanding common shares, which based on today’s outstanding shares would be 1,234,086 shares with a current value of approximately $1.9 million, plus shares of Class C, D and E non-convertible, non-voting preferred stock with a total liquidation preference of $22.7 million. The acquisition has been approved by the boards of directors of both companies and is expected to close by September 30, 2017, subject to customary conditions.
Based in San Antonio, Texas, CytoBioscience creates and manufactures instruments used in human cell research for drug development. It has a world-renowned scientific and technical staff, collaborative partnerships with leading pharmaceutical companies and strategic alliances with key groups and academic institutions. Its ion channel instrument was selected by the U.S. Food and Drug Administration (FDA) for its own cardiac safety testing on preclinical new drug compounds. CytoBioscience’s current order backlog is $6 million primarily in contract research work.
“This merger is transformative to Skyline Medical(SKLN) as it fulfills our goal of broadening our company’s business and brings immediate and meaningful revenue. It also brings a host of important medical center customers and relationships, including a Who’s Who in pharmaceutical product development, that we can leverage to increase awareness of the STREAMWAY System and generate sales,” said Dr. Carl Schwartz, chief executive officer of Skyline Medical. “Skyline Medical and CytoBioscience’s shared commitment to providing products and services that ensure the best possible patient outcomes will drive our operations and our strategic planning.”
Dr. Schwartz added, “With an exceptional intellectual property estate, CytoBioscience provides cell lines for ion channel safety testing to large pharmaceutical and biotechnology companies, a business that is expected to expand with FDA’s new requirement that all drugs be tested for cardiac safety. In particular, CytoBioscience’s contract research business has been growing rapidly and will allow Skyline investors to participate in this exciting sector. More than $50 million has been invested in CytoBioscience to date, much of it in the early days through grants by the government of Germany. We are delighted to bring these capabilities and relationships to Skyline and are very excited about the potential for our expanded operations.”
CytoBioscience designs and manufactures instruments for ion channel screening and protein solubility analytics, and has 11 U.S. and international patents on these technologies. It also provides in vitro contract research services and the cell lines, buffers, solutions and microchips used in the instruments it manufactures and in other instruments. In addition, it offers the only low-cost disposable shipping unit that can transport live cell, MEA plates or tissue samples within one-tenth a degree of 37°C for up to 100 hours.
Dr. James Garvin, chief executive officer of CytoBioscience, said, “This business combination is a positive for all parties as we leverage the strengths of each company to achieve greater success than either of us could alone. CytoBioscience is the leading provider of ion channel screening services in support of the CiPA initiative, which is intended by the FDA to move safety pharmacology from a predominantly pharmacodynamics approach to in silico and in vitro toxicity assessment. We are looking forward to converting our existing backlog to revenues and to accelerating the growth of our business. In addition, the STREAMWAY System represents a compelling solution to the problem of medical fluid waste disposal, and we are pleased to tap our network of contacts to raise awareness and drive sales.”
Upon the closing of the acquisition, Dr. Garvin will be named President of Skyline Medical(SKLN) and will be appointed to the Skyline Medical(SKLN) board of directors. Dr. Schwartz will remain chief executive officer and a director of Skyline. CytoBioscience’s 24 employees will continue to work in San Antonio and Skyline Medical’s headquarters will continue to be in Minneapolis.
Dr. Garvin has served as CEO of CytoBioscience since its relocation to the U.S. in 2015. He has deep experience in financing development stage healthcare companies. From 2013 to 2015 he was a managing director in investment banking for Divine Capital Markets. From 2007 through 2013 he served as chief operating officer for the Leedom Group. From 2000 to 2013 he was CEO of Obed Corporation, a company that worked on mergers and acquisitions in biotechnology as well as did micro finance projects in Africa and India.
Dr. Garvin holds a PhD in Urban Studies and Economic Systems and a Master’s of Administration from the University of New Orleans, and a BA in English Literature from the State University of New York at Albany.
Financial and Legal Advisors
Dawson James Securities Inc. served as financial advisor and Maslon LLP served as legal advisor to Skyline Medical(SKLN). Maynard Cooper Gale served as legal advisor to CytoBioscience.
Conference Call and Webcast
Skyline management will host a conference call with accompanying slides beginning at 11:00 a.m. Eastern time on August 15 to discuss this announcement as well as its second quarter 2017 financial results. To access the conference call, U.S.-based listeners should dial (844) 666-7589 and international listeners should dial (443) 961-0433. All listeners should provide passcode 68661783. Individuals interested in listening to the live conference call via the Internet may do so by logging on to the Company’s website at www.skylinemedical.com.
The slides that accompany the conference call prepared remarks will be posted to the Investors section of www.skylinemedical.com prior to the start of the call.
Following the conclusion of the conference call, a telephone replay will be available through August 21, 2017 and can be accessed by dialing (855) 859-2056 from within the U.S. or (404) 537-3406 from outside the U.S. All listeners should provide passcode 68661783. The webcast will be available for a time on the Company’s website.
DEADSKY, what's your basis for thinking tomorrow is the last day of dilution? I'm assuming u r guessing.
@236, ha yeah, the wife is dumping too. Maybe they r buying a new house or deluxe RV..
This is interesting.. The surge before another dump? A surge to entice new investors? Holding 10K at 0.2 keeping an eye on it. I assume it'll go back down to 0.1. Waiting for another weed surge in the markets.
Less than 100K shares for the Bid/ask to reach this level from 0.11 or so.
Time&Sales; http://imgur.com/a/g8nBW
Gee I don't know for sure, but probably the CEO..
Trying to sell my shares at .0993 (I mean .0991, ask keeps on lowering) from buying at .2. Probably won't even fill
Newest F-4 I see is 7/31. High volume again certainly would suggest more inside selling/dilution! I may have bought too high at 0.2!
This is a cruddy time for him to be selling... doesn't he know that it's better to sell into strength?? Why is he taking such a loss himself?
DRYS is very risky. Shorts are greedy, will try to hold it down. New traders getting sucked into this stock every time. Look at the chart history. It doesn't deserve any volume.